These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 15059906)
1. Endogenous control of cell cycle progression by autocrine transforming growth factor beta in breast cancer cells. Ammanamanchi S; Tillekeratne MP; Ko TC; Brattain MG Cancer Res; 2004 Apr; 64(7):2509-15. PubMed ID: 15059906 [TBL] [Abstract][Full Text] [Related]
2. Autocrine and exogenous transforming growth factor beta control cell cycle inhibition through pathways with different sensitivity. Wang J; Sergina N; Ko TC; Gong J; Brattain MG J Biol Chem; 2004 Sep; 279(38):40237-44. PubMed ID: 15271980 [TBL] [Abstract][Full Text] [Related]
3. BCL-x(L) and BCL2 delay Myc-induced cell cycle entry through elevation of p27 and inhibition of G1 cyclin-dependent kinases. Greider C; Chattopadhyay A; Parkhurst C; Yang E Oncogene; 2002 Nov; 21(51):7765-75. PubMed ID: 12420213 [TBL] [Abstract][Full Text] [Related]
4. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. Di Gennaro E; Barbarino M; Bruzzese F; De Lorenzo S; Caraglia M; Abbruzzese A; Avallone A; Comella P; Caponigro F; Pepe S; Budillon A J Cell Physiol; 2003 Apr; 195(1):139-50. PubMed ID: 12599217 [TBL] [Abstract][Full Text] [Related]
5. Mechanisms of cell cycle arrest in response to TGF-beta in progestin-dependent and -independent growth of mammary tumors. Salatino M; Labriola L; Schillaci R; Charreau EH; Elizalde PV Exp Cell Res; 2001 Apr; 265(1):152-66. PubMed ID: 11281653 [TBL] [Abstract][Full Text] [Related]
6. TGF-beta 1 induces the cyclin-dependent kinase inhibitor p27Kip1 mRNA and protein in murine B cells. Kamesaki H; Nishizawa K; Michaud GY; Cossman J; Kiyono T J Immunol; 1998 Jan; 160(2):770-7. PubMed ID: 9551912 [TBL] [Abstract][Full Text] [Related]
7. Induction of G1 phase arrest in MCF human breast cancer cells by pentagalloylglucose through the down-regulation of CDK4 and CDK2 activities and up-regulation of the CDK inhibitors p27(Kip) and p21(Cip). Chen WJ; Chang CY; Lin JK Biochem Pharmacol; 2003 Jun; 65(11):1777-85. PubMed ID: 12781329 [TBL] [Abstract][Full Text] [Related]
8. Effects of TGF-beta 1 (transforming growth factor-beta 1) on the cell cycle regulation of human breast adenocarcinoma (MCF-7) cells. Mazars P; Barboule N; Baldin V; Vidal S; Ducommun B; Valette A FEBS Lett; 1995 Apr; 362(3):295-300. PubMed ID: 7729516 [TBL] [Abstract][Full Text] [Related]
9. Transforming growth factor beta 1 increases the stability of p21/WAF1/CIP1 protein and inhibits CDK2 kinase activity in human colon carcinoma FET cells. Gong J; Ammanamanchi S; Ko TC; Brattain MG Cancer Res; 2003 Jun; 63(12):3340-6. PubMed ID: 12810668 [TBL] [Abstract][Full Text] [Related]
10. TGF-beta-mediated cell cycle arrest of HPV16-immortalized human ectocervical cells correlates with decreased E6/E7 mRNA and increased p53 and p21(WAF-1) expression. Rorke EA; Zhang D; Choo CK; Eckert RL; Jacobberger JW Exp Cell Res; 2000 Aug; 259(1):149-57. PubMed ID: 10942587 [TBL] [Abstract][Full Text] [Related]
11. Differential effects of transforming growth factor on cell cycle regulatory molecules in human myeloid leukemia cells. Hu X; Zhang X; Zhong Q; Fisher AB; Bryington M; Zuckerman KS Oncogene; 2001 Oct; 20(47):6840-50. PubMed ID: 11687963 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of MCF-7 breast cancer cell proliferation by 5alpha-dihydrotestosterone; a role for p21(Cip1/Waf1). Greeve MA; Allan RK; Harvey JM; Bentel JM J Mol Endocrinol; 2004 Jun; 32(3):793-810. PubMed ID: 15171713 [TBL] [Abstract][Full Text] [Related]
13. Overexpression of transforming growth factor (TGF) beta1 type II receptor restores TGF-beta1 sensitivity and signaling in human prostate cancer cells. Guo Y; Kyprianou N Cell Growth Differ; 1998 Feb; 9(2):185-93. PubMed ID: 9486855 [TBL] [Abstract][Full Text] [Related]
14. Blockade of tumor cell transforming growth factor-betas enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy. Ohmori T; Yang JL; Price JO; Arteaga CL Exp Cell Res; 1998 Dec; 245(2):350-9. PubMed ID: 9851876 [TBL] [Abstract][Full Text] [Related]
15. Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase. Hsieh FF; Barnett LA; Green WF; Freedman K; Matushansky I; Skoultchi AI; Kelley LL Blood; 2000 Oct; 96(8):2746-54. PubMed ID: 11023508 [TBL] [Abstract][Full Text] [Related]
17. A kinase-defective transforming growth factor-beta receptor type II is a dominant-negative regulator for human breast carcinoma MCF-7 cells. Ko Y; Koli KM; Banerji SS; Li W; Zborowska E; Willson JK; Brattain MG; Arteaga CL Int J Oncol; 1998 Jan; 12(1):87-94. PubMed ID: 9454891 [TBL] [Abstract][Full Text] [Related]
18. Insensitivity to growth inhibition by TGF-beta1 correlates with a lack of inhibition of the CDK2 activity in prostate carcinoma cells. Cipriano SC; Chen YQ Oncogene; 1998 Sep; 17(12):1549-56. PubMed ID: 9794232 [TBL] [Abstract][Full Text] [Related]
20. Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens. Carroll JS; Swarbrick A; Musgrove EA; Sutherland RL Cancer Res; 2002 Jun; 62(11):3126-31. PubMed ID: 12036924 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]